Medroxyprogesterone detailed information

Medroxyprogesterone detailed information

Clinical data
ATC code	G03AC06 (WHO) G03DA02 (WHO), L02AB02 (WHO)
Pharmacokinetic data
Protein binding	90%
Elimination half-life	50 days
Identifiers
IUPAC name 17-acetyl-17-hydroxy- 6,10,13-trimethyl- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one
CAS Number	520-85-4
PubChem CID	10631
DrugBank	APRD00627
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H32O3
Molar mass	344.488 g/mol

WikiDoc Resources for Medroxyprogesterone detailed information
Articles
Most recent articles on Medroxyprogesterone detailed information Most cited articles on Medroxyprogesterone detailed information Review articles on Medroxyprogesterone detailed information Articles on Medroxyprogesterone detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Medroxyprogesterone detailed information Images of Medroxyprogesterone detailed information Photos of Medroxyprogesterone detailed information Podcasts & MP3s on Medroxyprogesterone detailed information Videos on Medroxyprogesterone detailed information
Evidence Based Medicine
Cochrane Collaboration on Medroxyprogesterone detailed information Bandolier on Medroxyprogesterone detailed information TRIP on Medroxyprogesterone detailed information
Clinical Trials
Ongoing Trials on Medroxyprogesterone detailed information at Clinical Trials.gov Trial results on Medroxyprogesterone detailed information Clinical Trials on Medroxyprogesterone detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Medroxyprogesterone detailed information NICE Guidance on Medroxyprogesterone detailed information NHS PRODIGY Guidance FDA on Medroxyprogesterone detailed information CDC on Medroxyprogesterone detailed information
Books
Books on Medroxyprogesterone detailed information
News
Medroxyprogesterone detailed information in the news Be alerted to news on Medroxyprogesterone detailed information News trends on Medroxyprogesterone detailed information
Commentary
Blogs on Medroxyprogesterone detailed information
Definitions
Definitions of Medroxyprogesterone detailed information
Patient Resources / Community
Patient resources on Medroxyprogesterone detailed information Discussion groups on Medroxyprogesterone detailed information Patient Handouts on Medroxyprogesterone detailed information Directions to Hospitals Treating Medroxyprogesterone detailed information Risk calculators and risk factors for Medroxyprogesterone detailed information
Healthcare Provider Resources
Symptoms of Medroxyprogesterone detailed information Causes & Risk Factors for Medroxyprogesterone detailed information Diagnostic studies for Medroxyprogesterone detailed information Treatment of Medroxyprogesterone detailed information
Continuing Medical Education (CME)
CME Programs on Medroxyprogesterone detailed information
International
Medroxyprogesterone detailed information en Espanol Medroxyprogesterone detailed information en Francais
Business
Medroxyprogesterone detailed information in the Marketplace Patents on Medroxyprogesterone detailed information
Experimental / Informatics
List of terms related to Medroxyprogesterone detailed information

For patient information, click here.

Medroxyprogesterone is a progestin, and is commonly a component of hormonal contraceptives. It can be used in the treatment of endometriosis, abnormal menstrual bleeding or amenorrhea. Possible side effects include weight gain, depression, and irregular menses or amenorrhea.

See also

• Progestin
• Depo Provera
• Medroxyprogesterone acetate treatment